P H A R M A C E U T I C A L S
We aim at accelerating the development of new therapeutic options for patients with cancer
INVIVIS Pharmaceuticals is a clinical stage oncology startup.
Our primary goal is to deliver new, efficiently developed cancer drugs.
Our specialization and nimble operations assure cost-efficient and rapid development.
Invivis has unrivaled knowledge capital supporting relevant strategic choices. Hands-on professionals, with 20 years oncology drug experience from diverse pharmaceutical corporations, are working together with a world-class scientific committee.
INVIVIS Pharmaceuticals is incorporated in the EU and in the US, allowing expert knowledge capital and relevant networks to build best in class cancer drug discovery.
Barthelemy O. Gilles
COO & Co-founder
Erard M. Gilles
CEO & Founder
Gerd Hummel
SVP Discovery
Bios <
Jean-Yves Blay is President of the EORTC.
He is also Professor of Medicine in Medical Oncology at the Université Claude Bernard in Lyon, France, currently Head of the Medical Oncology Department and the Institute for Clinical Science at the Centre Leon Berard, the regional Cancer Center in Lyon France,
Dr. Blay obtained his medical degree in 1990 specialising in oncology. In 1994 he received his PhD from the Université Claude Bernard, for his research on the role of interleukin 6 in tumour progression and resistance to treatment in renal cell carcinomas.
He also holds a Master in Biological Oncology Bases Fondamentales de l'Oncogénèse, 1988, Paris VII, and a Masters in Statistics, Paris XI, in1989.
Since 2001, Dr. Blay has served as Chairman of the French Sarcoma Group and currently acts as the Network Director of Conticanet, a network of excellence funded by the EU commission dedicated to novel treatment approaches in sarcomas.
At the EORTC, Dr Blay has been active in the Translational Research Advisory Committee, the Protocol Review Committee, and as a faculty member on EORTC educational programs. He is the former Chair of the EORTC Soft Tissue and Bone Sarcoma Group.
Dr. Blay is an active member of a number of professional groups including the American Society of Clinical Oncology, the American Association for Cancer Research, the American Society of Haematology, the Connective Tissue Oncology Society (Board member 2001-2004), the French Society of Cancer (Board member 2005-2011), the European Association of Cancer research, and the European Society of Medical Oncology (National Representative for France).
Dr. Blay has co-authored more than 250 peer-reviewed articles and over 200 abstracts and book chapters, with an H factor of 41. He has trained 8 Ph.D. Students, and 21 M.D. thesis, and has participated to more than 40 jury of thesis, in national and international universities (Belgium, The Netherlands, Vietnam, New-Zealand)
Dr Blay is currently serving as the President of the European Organisation for Research and Treatment of Cancer (EORTC).
Professor at the University of Texas M. D. Anderson Cancer Center, holds the Barnts Family Distinguished Chair for Cancer Research. His administrative appointment is Deputy Chairman, Department of Experimental Therapeutics.
Dr. Plunkett is particularly interested in education of the next generation of scientists. He has been a member of the University of Texas Graduate School of Biomedical Sciences at Houston since 1976.
His activities in graduate education have been recognized by his election to President of the Faculty of The Graduate School of Biomedical Sciences, and the award of the 1st Sowell-Huggins Professorship in Cancer Research in that school.
His major research pursuits are related to development of novel therapeutics based on knowledge of cellular responses to DNA damage, and elucidating the mechanisms of drug action, particularly of nucleoside analogs.
His investigations demonstrated multiple mechanism of action for both fludarabine and gemcitabine, as well as the mechanisms of other nucleosides.
Additional research interests involves mechanisms for rapidly activating cell death processes in tumors that are dependent on particular oncogenes, and matching genetic lesions in tumor cells with specific mechanisms of single agents or combinations.
He has enjoyed sustained and dedicated collaborations with his colleagues involved with clinical research, interactions that have resulted in advances in clinical treatments that induce remissions more effectively which are maintained longer than previously possible in leukemias.
He was the recipient of the Service to Mankind Award from the Leukemia Society of America in 1989, the Faculty Achievement Award in Clinical Research in 1996, and the 1st Potu N. Rao award for Excellence in Basic Research in 2006.
He also has the title of Associate Vice President, Research Integrity, and is the Institutional Research Integrity Officer.
Dr. Anthony W. Tolcher is the Director of Clinical Research at START (South Texas Accelerated Research Therapeutics) in San Antonio, Texas. Dr. Tolchers major interest is in the development of new anticancer agents, with a special interest in molecular genetic targets for cancer therapy.
He is a graduate of the University of British Columbia in Vancouver, Canada. He performed his residency in internal medicine at the University of Toronto and his fellowship in oncology at the University of British Columbia. He followed this with a research fellowship at the National Cancer Institute, Bethesda, Maryland. Dr. Tolcher was the Director of Clinical Research at the Cancer Therapy and Research Center (CTRC) in San Antonio from 2003 until April, 2007, and prior to that served as the Associate Director at the CTRC from 1999 to 2003.
Dr. Tolchers major interest is in the development of new anticancer agents, with a special interest in molecular genetic targets for cancer therapy.
He was a Fogarty Fellow at the National Institute of Health, and received the Murray Muirhead Award for humanitarian and academic excellence, and the Goel Prize in Medicine for excellence in the Clinical Disciplines.
He is a Fellow of the Royal College of Physicians of Canada; a Diplomate of the American Board of Internal Medicine and Medical Oncology; a Fellow of the American College of Physicians, and a member of the American Association for Cancer Research, the American Society of Clinical Oncologists, and the European Society for Medical Oncology. He also serves as a member of the American Society of Clinical Oncology Scientific Program Committee and the Cancer Education Committee.
He is an Associate Editor of the The Journal of New Anticancer Agents; and he is a scientific grant reviewer for the National Cancer Institute of Canada. Dr. Tolcher has authored numerous publications, including 38 peer reviewed publications, 26 Conference Proceedings, and 5 book chapters. He serves as a reviewer for the following journals: Anti-Cancer Drugs, Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research, Clinical Lung Cancer, Clinical Prostate Cancer, Human Gene Therapy, and the Journal of Cancer.
Invivis is a clinical-stage development company.
Its research strategy has two aspects :
- Rediscovery through the evaluation of missed opportunities in the light of modern science. Some drugs may have had insufficient activity because the targeted disease was not well defined at the time of testing. This effort essentially hinges on progresses made during the clinical stage, as well as on the characterization of adequate biomarkers.
Partnering with academic centers is also an important aspect of reengineering projects.
- Streamlining and fitting the development process and knowledge to the oncology sector only. This ensures efficient allocation and concentration of resources.
Generally, Invivis' methodology is:
- to reevaluate the many so-called negative trials for promising agents, which were identified as inconclusive based on stringent regulatory criteria, using more flexible statistical methodology
- to reevaluated the overall consistency of data, and
- to identify discrepancies that cast doubt about the overall observed activity vs. what would be expected, for example through computer simulations and the use of different assumptions.
When a promising agent is identified, the drug candidate is evaluated in principle based on the state of the art by our scientific committee. We assess the pertinence, the current competitive landscape, and the known but unpublished issues or roadblocks.
Through deeper investigation we try to generate new biomarkers or to find factors to set the rationale for improved clinical trials designs, which would likely result in positive outcomes based on prior knowledge.
IVV-1001 is an antiprogestin, an anti-hormone used in breast cancer treatments.
Invivis has defined a predictive biomarker for this drug, and enhanced activity is expected in a better characterized patient population. Invivis is also defining a new biomarker for antiestrogens for the same purpose.
Current research revolves around the different clinical activities of the many tyrosine-kinases and anti-angiogenic agents to redevelop promising agents that did not find their right disease target.
The second area of particular interest to Invivis is antimetabolic agents.
Invivis Pharmaceuticals is a privately held company, fully owned by its founders.
Its operations have been made sustainable by its 2010 founders' initial funding and the licensing out of its first project IVV-1001; an antihormone (antiprogestin) used in breast cancer.
Upon the near future, Invivis' pipe line will open up new projects to investors.
Investor inquiries are welcome.
- February 14, 2012:
INVIVIS PHARMACEUTICALS Inc. grants Exclusive Worldwide Licensing Agreement to Arno Therapeutics, Inc. (OTCBB: ARNI) for the development of cancer drug ...
- August 2011:
PHARMALEAD THERAPEUTICS Inc. improves its brand recognition and performance in definitively adopting as its corporate name I NVIVIS Pharmaceuticals Inc.
- December, 28th, 2010:
Registration of INVIVIS SAS in Orsay (91, France)
- November 6th, 2010 :
PHARMALEAD THERAPEUTICS Inc. awarded by U.S. Qualifying Therapeutic Discovery Project Grant Program
- June 14th, 2010:
PHARMALEAD THERAPEUTICS Pre-IND granted by AFFSAPS (France) for IVV-1001
- January, 1st, 2010:
Incorporation of PHARMALEAD THERAPEUTICS In Bridgewater (New Jersey, USA)
>> More
In the US
Invivis Pharmaceuticals Inc.
547 Meadow Road
Bridgewater, New Jersey - 08807
U.S.A.
P: +1 (908) 818-9393
F: +1 (888) 591-1834
In the EU
Invivis Pharmaceuticals SAS
2, rue Jean Rostand
91400 Orsay
France
T: +33 (0)180 864 902
F: +33 (0)180 864 903
Invivis SVP Discovery, Research and Preclinical Development
Dr. Gerd Hummel is a career medicinal chemist and preclinical research and development leader with comprehensive experience in strategic R&D development, business development and intellectual property management.
His focus is creating efficient and effective R&D operations to meet organizational goals and ensure financial success by leading discovery of emerging medicinal technology.
Dr. Hummels expertise in medicinal chemistry and research management aligns business and scientific objectives. He has over 30 patents and patent applications combined with more than 10 years business management experience for Jerini AG in Germany. He has significant experience managing scientific departments, budget planning and due diligence for R&D procedures. His experience in safety, legal and analytical processes has proven beneficial as Senior Director of Jerini AG.
Dr. Hummel has a doctorate in Organic Chemistry in addition to masters degrees in Organic Chemistry and Project Management. He received his PhD in organic chemistry from the University of Konstanz, Germany. From 1996 to 1998 he was a postdoctoral fellow at The Burnham Institute in San Diego, USA, and at the University of Edmonton, Canada. He also completed an international executive program for general management. His preclinical experience is diverse and includes indications including oncology, ophthalmology and pain/inflammation.
Dr. Hummel is a proactive leader and mentor for scientific departments and communicates with legal, regulatory and scientific leaders to ensure effective and organized laboratory operations. His leadership in analytical and scientific discovery has been paramount in his career.
Dr. Hummels scientific knowledge, innovative methodologies, R&D experience, and motivational leadership skills will create business success for his new venture as SVP Discovery, Research and Preclinical Development of Invivis Pharmaceuticals.
Dr. Francois Lokiec is expert in oncological pharmacology. He is currently heading a pharmacokinetics department serving two cancer centers: the Curie Institute (Institut Curie, Paris - France) and the Rene Huguenin Institute (Institut Rene Huguenin, Saint-Cloud - France).
Dr. Francois Lokiec has a PharmD degree and a PhD on radio-element applications in pharmacology.
He teaches regularly in multiple universities and is Expert to the EMEA for Oncology Drugs Pharmacology.
He authored more than 180 peer-reviewed publications and more than 200 communications in conventions.
Prof. Martine J. Piccart is Professor of Oncology at the Université Libre de Bruxelles (ULB) and Director of the Medicine Department at the Institut Jules Bordet, in Brussels, Belgium.
Prof. Piccart earned her M.D. and Ph.D. at the Université Libre de Bruxelles, Belgium, and received her oncology qualifications in New York and London. She is a member of the Académie Royale de Médecine de Belgique.
With a primary interest in breast cancer and drug development, Prof. Piccart has a strong interest in international research collaboration, and is the principal or co-principal investigator of many clinical trials, including HERA, MINDACT, and ALTTO. She is co-founder and chair of the Brussels-based Breast International Group (BIG), created in 1996 to facilitate international breast cancer clinical trials, and TRANSBIG, a European Commission supported translational research consortium to complement BIGs clinical research network.
Prof. Piccart is an active member of many professional organizations, currently serving as president-elect of the European Society for Medical Oncology (ESMO). She is immediate past-president of the European Organization for the Research and Treatment of Cancer (EORTC) and recently served on the American Society of Clinical Oncology (ASCO) Board.
She is author or co-author of more than 300 scientific publications in peer-reviewed journals and has received numerous prestigious awards for her contribution to research in oncology, including the ESMO Award for Exceptional Contribution to the Advancement of Medical Oncology in Europe (1997), a Jacqueline Seroussi Memorial Foundation for Cancer Research Award for "International leadership in translational and clinical research that has improved treatment outcomes for women with early stage and advanced breast cancer" (2005), the 14th Claude Jacquillat Award for achievements in clinical oncology (2006) and the ESMO-GSK Lifetime Achievement Award in Breast Cancer Research (in 2006). She was awarded the Miami Breast Cancer Conference Award of Excellence for 2007 and the Jill Rose Award for distinguished biomedical research in October 2009 in New-York. More recently, Prof. Piccart received the William L. McGuire Award in recognition of her contribution in breast cancer research in December 2009 in San Antonio.
Summary of scientific production
335 communications and lectures; 440 published abstracts; 54 published book chapters and 327 published articles (75 as first author, 111 as senior author).
is Invivis' C.E.O. & C.M.O.
Dr. Erard M. Gilles is a career clinical oncology physician, research director and pharmaceutical research and development leader with extensive experience in clinical trial design and operations, regulatory submissions and tactical pharmaceutical development.
His passion is incorporating his medical and biostatistical subject matter expertise with his proactive leadership and global R&D knowledge to streamline and forge efficient drug development paths for critical new drugs and oncology applications.
Dr. Gilles' experience in diverse global R&D operations and emerging oncology pharmaceuticals provides comprehensive leadership in international relations and regulatory submissions, tactical planning and business network relationships. He has 18 years of experience leading clinical development for premier corporations in multicultural environments, including Johnson & Johnson, Genta, Inc, Aventis Pharmaceuticals and Roche Pharmaceuticals.
In addition to his expertise in clinical research development, Dr. Gilles has proven leadership abilities in marketing and business development. He served as Head of R&D, Medical Affairs and Marketing at Pharmacia where he doubled annual sales through sales team building, proactive regulatory lifecycle management and product launch development.
He has multiple master's degrees in advanced pharmacology, biostatistics and business administration to combine scientific, business operations and regulatory knowledge to ensure comprehensive R&D support. He has recently developed benchmarking studies, identified calculation issues for a product in development and provided key oversight for 2 separate pharmaceuticals.
He has registered two patents on breast cancer biomarkers in 2011.
Dr. Gilles has a diverse network of relationships with regulatory leaders, key opinion leaders and pharmaceutical corporate professionals. His ability to proactively implement improvements for oncology drug development during time sensitive projects is outstanding. His relationships with European regulatory agencies, the National Cancer Institute, the FDA and prominent statisticians have proven critical for the success of numerous pharmaceutical companies.
Dr. Gilles' leadership and management style, regulatory knowledge, drug development experience and marketing strategies provide the critical base for success in his new venture as CEO & CMO of Invivis Pharmaceuticals.
He serves as Chairman of the GERCOR multidisciplinary cancer research group and is a member of the French Cancer Society, French Internal Medicine Society, American Society of Clinical Oncology, and European Society for Medical Oncology.
Pr. Aimery de Gramont has been Professor of Oncology since 1993 and Head of the Oncology Department since 2002. He earned his MD degree from the Faculty of Medicine in Paris, France and subsequently served an internship residency at Paris Hospitals and a residency at Laval University in Quebec, Canada.
Pr. de Gramont is co-Chairman of the scientific board of the International Society of Gasrrointestinal Oncology and was a member of the editorial board of the Journal of Clinical Oncology. He has authored or coauthored more than 200 journal articles and been an invited speaker in more than 30 countries.
Pr. de Gramont's fundamental and preclinical research has focused primarily on the fields of cytogenetics, molecular biology, targeted therapies and adoptive immunotherapy, specifically in the areas of hematologic cytogenetics, cellular membranes in nocturnal paroxystic hemoglobinuria, activated macrophage adoptive immunotherapy, development and modulation of antimetabolites, and preclinical drug development. His clinical research has involved mainly haematology, gastro-intestinal and ovarian cancer therapy. He is team leader of the Group of Cancer Biology and Therapeutics, INSERM U8106 and Université Pierre et Marie Curie, (23 persons) since 2005.
As a member of GERCOD and GERCOR, Pr. de Gramont has played a pivotal role in a colon cancer program that has included 7 first-line phase II, 13 second-line phase II, 5 first-line phase III, and 2 adjuvant studies involving almost 6000 patients since 1984. He has served as chairman or cochairman on over 20 different protocols.
is Invivis' COO and Co-Founder.
Mr. Gilles' entrepreneurial and proven marketing expertises provide important foundation for business effectiveness and growth in his new venture as COO with Invivis Pharmaceuticals.
Barthélemy Gilles has served as founder and co-founder of several successful entrepreneurial companies and led marketing, sales and general operations to ensure startup successes. His commitment to a diversified sales approach, efficient operations and strategic market development to capture long term company growth has been a key asset for the profitability of these organizations.
Mr. Gilles brings marketing knowledge and design innovation from the highly technical, competitive aeronautical and IT industries. He has 20 years of experience leading market positions in these markets, strategic planning, product development and communications as co-founder for Aerocorp Corporate Aeronautics and Metalinks Natural Interfaces and as senior leadership in sales for companies including Aviaxess Helicopter & Jet, Groupe Hamelin and Bandaï.
He has a master's degree in International Marketing and a bachelor's degree in Economics. His business focus and interests include economic intelligence, knowledge management and commercial intelligence. His ability to incorporate trends and intelligence into business development has been critical throughout his career.
Mr. Gilles' entrepreneurial expertise and proven marketing expertise provide an important foundation for business effectiveness and growth in his new venture as COO with Invivis Pharmaceuticals.
Michel E. Marty is currently Professor of Oncology,
Director of Centre for Therapeutic Innovation in Oncology and Hematology in Saint Louis University Hospital (Paris, France),
President of the yearly congress Eurocancer,
Chairman of the Oncology Working Party at the French Drug Agency (AFSSAPS) and of the SAG-Oncology at the EMEA.
Prior to these positions, Pr.Marty was Director of Therapeutic Research of Gustave Roussy Institute (Villejuif), Head of the Department of Oncology in Saint Louis University Hospital in Paris (France), and he was the chairman of the International Cancer Collaborative Study Group.
His main areas of research are:
- Molecular biology of breast cancers in relation to prognosis and drug sensitivity
- Primary and adjuvant chemotherapy of localized breast cancers
- Systemic therapy of metastatic breast cancers, identification-validation of biomarkers
- Phase I & II clinical trials and gene therapy.
Dr.Marty received his medical degree from the University Paris VII (France).
He completed a fellowship in haematology and medical Oncology and was nominated as a Professor of Oncology in 1978.
Pr Marty is the author or coauthor of 450 scientific articles, book chapters and communications, mostly in the field of drug development and cancer therapy (list upon request).
Pr. Alexander Eggermont, M.D., Ph.D., is Director of Gustave Roussy (Villejuif, Paris), Full Professor of Surgical Oncology and Head of the Department of Surgical Oncology at the Erasmus University Medical Center Daniel den Hoed Cancer Center in Rotterdam.
- Chair in Experimental Surgical Oncology endowed by the Dutch Cancer Society (1997).
- Chair in Oncology e Causa Honoris (2003): the Joseph Maisin Chair at the Catholique University of Leuven in Belgium.
- PhD thesis on Interferon and IFN-Inducers in the Treatment of Cancer at the Erasmus University Rotterdam (1987)
Clinical Specialties / Research
Melanoma, Sarcoma and regional therapy techniques (TNF-based Isolated limb perfusion program in
Europe). General drug development and clinical trial methodology.
Past Chair EORTC MG Group, Current Chair Adjuvant therapy committee EORTC Melanoma Group.
Basic and Translational Research
Created Laboratory for Experimental Surgical Oncology together with Timor ten Hagen. LECO is specialized in tumor pathophysiology (innovative intravital microscopy models) Nanotechnology for drug targeting, tumor
vasculature and tumor biology. Biomarker program in Melanoma.
International functions
EORTC, FECS, ECCO, ASCO, AACR, NCI, other:
- European Academy of Cancer Sciences: First President (2009-2013),
- ECCO (European CanCer Organisation) : Current President (2008-2010),
- EORTC: Immediate past President of EORTC (European Organization for Research and Treatment of Cancer) and past Chairman of the Melanoma Group. Currently chairs the Steering Committee of NOCI (Network of Core Institutes) and the Committee on Adjuvant Treatment Strategies of the EORTC-Melanoma Group,
- ASCO: Member of Board of Directors of ASCO (Surgical Oncology Seat) 2005-2008. Past chairman on the International Affairs committee of ASCO. Serves on JCO Editorial Board,
- AACR: Member Translational Reseaerch Committee and AACR Centennial Committee International Affairs Committee and the Tumor Immunology Committee,
- Deputy Editor of Clinical Cancer Research. EORTC Program Chair EORTC-NCI-AACR molecular targets and cancer therapeutics. Co-Chair AACR Tumor Immunology Conferences,
- NCI: Serves on the NCI-CTEP advisory board. rds at national and international cancer institutes, cancer leagues, grant-funding programs, training pr,
- Other: He serves on scientific advisory boaograms and is a board member of various scientific societies and journals.
Scientific output
He is author/coauthor of > 500 peer reviewed publications, book chapters and monographs,
> 25 PhD thesis out of his clinical and basic laboratory programs at Erasmus University MC Rotterdam.
Dr. Corinne Segalen, M.D., has been General Manager for IMS Health in France since 2004.
IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries.
She was previously serving at Digene, a diagnostics corporation specialized in tumour virology, as General Manager for France.
Prior to Digene, she led the French and Belgian affiliates at NovoNordisk, a world leader in diabetes care.
Corinne, who initially trained as a physician, also has held a number of positions at Pharmacia and Upjohn, including Head of Marketing & Hospital Sales.
Director of Cancer Drug Development Program at University of Cincinnati of Medicine, Cincinnati (USA)
Pr. Olivier Rixe, MD, PhD, received his medical degree from the Pierre and Marie Curie University, Paris, France, followed by a training in medical oncology and internal medicine which he completed at University of Paris in 1988.
He spent one year in 1991 in the NCI's Medicine Branch under the direction of Dr Tito Fojo.
Following his stay at the NCI, Dr Rixe received his PhD in Molecular Biology from Diderot University in Paris.
He then served as a senior medical oncologist at the Gustave-Roussy Institute, Villejuif, France and was appointed Professor of medical oncology in 2004 in Pierre and Marie Curie University.
Pr Rixe joined the NCI in February 2008 as a full time physician in the Medical Oncology Branch.
Research
Pr Rixe's main interest in cancer research has focused on (1) Preclinical research studying the problem of drug resistance; (2) Investigations evaluating the feasibility of gene therapy as an anti-cancer therapy; and (3) Clinical research with the goal of evaluating and developing new anticancer agents for all cancers, with a focus recently on renal cell carcinoma. Active in numerous drug trials, Pr. Rixe has been involved in the development of such agents as oxaliplatin, camptothecins, and taxanes, as well as targeted therapies including the antiangiogenic compounds sunitinib, axitinib and VEGF-trap.
Pr Rixe's clinical trials interest focus on two major areas: the treatment of kidney cancer and early drug development.
Complementing his research endeavors, Pr. Rixe has authored or co-authored more than 100 scientific articles. Pr. Rixe is a member of several professional organizations, including the American Society of Clinical Oncology, American Association for Cancer Research, and European Society for Medical Oncology.
For the past three years, he has served as Chairman of the French Kidney Cancer Specialized Program of Research Excellence (SPORE).
Dr. Monk is a tenured Associate Professor and the Director of Research in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, at the Chao Family Comprehensive Cancer Center, UCI Medical Center, Orange, California, USA.
Education/History
Bradley J. Monk, MD, graduated at the top of his class from the University of Arizona College of Medicine in 1988, and completed a residency in obstetrics and gynecology at the University of California, Los Angeles, in 1992. He is the recipient of three fellowships: in medical genetics from the National Institutes of Health, Bethesda, Maryland (1988); in gynecologic oncology as a Felix Rutledge Fellow from the M.D. Anderson Cancer Center, Houston, Texas (1990); and in gynecologic oncology from the University of California, Irvine (UCI) (1992-1995). In 1995, Dr. Monk was appointed director of gynecologic oncology at Texas Tech University Health Services Center, and, in addition, in 1996, he became associate medical director of the Southwest Cancer Center, both in Lubbock, Texas. Since 1998, Dr. Monk has been at the University of California, Irvine where he became tenured associate professor of obstetrics and gynecology in the department of OB/GYN in 2004. He is board certified by the American Board of Obstetricians and Gynecologists, with subspecialty certification in Gynecologic Oncology.
Professional Society Affiliations
Dr. Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists, and the American Society for Colposcopy and Cervical Pathology. He is also a full active member of the Society of Gynecologic Oncologists, the American Society of Clinical Oncology, and the American Association for Cancer Research, among numerous other professional organizations.
Publications/Editorial Experience
Dr. Monk serves as a reviewer for several peer-reviewed journals, including Clinical Cancer Research, Obstetrics and Gynecology, Cancer, and The Journal of Clinical Oncology. He currently sits on the editorial boards of Community Oncology, American Journal of Hematology/Oncology, Gynecologic Oncology and Clinical Ovarian Cancer. He has authored or co-authored numerous textbook chapters and more than 120 articles in peer-reviewed journals dealing predominantly with the prevention and chemotherapy of gynecologic malignancies, and with quality-of-life (QOL) aspects of cancer care.
Research Interests
Dr. Monk's research focuses on areas that include chemotherapeutic agents used to treat ovarian and cervical carcinoma; etiology, clinical significance, and prevention of postoperative adhesions following radical pelvic surgery; biomarkers in gynecologic cancers; human papillomavirus (HPV) infection in women; and QOL issues in advanced ovarian cancer patients. Dr. Monk has been an investigator for the Gynecologic Oncology Group (GOG) since 1995. There, he serves as the Group's Cervical and Vulvar Committee Chair and also as a member of the Tissue Utilization, Publications, and Protocol Development committees. Dr. Monk has also received career-development funding from the National Cancer Institute to investigate strategies against HPV-related genital diseases in women.
Director of the Center for Sarcoma and Bone Oncology at DFCI, director of the Ludwig Center at Dana-Farber/Harvard Cancer Center (MA), executive director for Clinical and Translational Research at the Ludwig Institute for Cancer Research (U.S.A.)
Pr. Demetri received an undergraduate degree from Harvard University and a medical degree from Stanford University School of Medicine. After completing Internal Medicine residency and chief residency at the University of Washington Hospitals in Seattle, Washington, he pursued a fellowship in Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an attending physician since 1989. Pr. Demetri serves as co-chair of the Medical Advisory Board for the Sarcoma Alliance for Research through Collaboration (SARC) and Executive Director for Clinical and Translational Research in the Ludwig Center for Cancer Research, the largest philanthropic organization supporting cancer research.
Interests
Translation of Differentiation Research into Clinical Therapeutics, Translational Clinical Trials of Hematopoietic Cytokines, Clinical Guideline Development Process
Pr. Demetri's research and clinical interests have focused on the development of targeted therapies for sarcomas and other solid tumors. The contributions of Pr. Demetri and his colleagues at Dana-Farber/Harvard Cancer Center have led to the development of cancer treatments such as Gleevec and Sutent.
Recent Awards
- Claire W. and Richard P. Morse Research Award, 2005
- Emil J. Freireich Award in Clinical Cancer Research, 2002
- Focused Giving Program Award, Johnson and Johnson Foundation, 1993
Publications
Pr. Demetri has authored and co-authored several hundreds of articles and publications, available upon request.
Pharmalead Therapeutics Inc. (today Invivis Pharmaceuticals) awarded approximately $250,000 under U.S. the U.S. Qualifying Therapeutic Discovery Project Grant Program
Bridgewater, NJ (USA), Orsay, 91 (France),
November 5, 2010.
Pharmalead Therapeutics Inc. today announced it has been granted $250,000 under the Qualifying Therapeutic Discovery Project program, which is part of the U.S. Patient Protection and Affordable Care Act.
One application was submitted under this program related to work with IVV-1001, the company's anti-progestin drug against breast cancer. The maximum grant was awarded to this starting project.
M. Erard Gilles, M.D., MsC., Chief Executive Officer, said: "We are pleased to be awarded this grant, which we believe is a testimony of the potential of our work to develop innovative and affordable medicines for cancer patients, and a gratifying support to our strategic positioning in a difficult economic environment."
About the Qualifying Therapeutic Discovery Project program:
The Qualifying Therapeutic Discovery Project tax credit, which can also be administered as a grant, is provided under section 48D of the U.S. Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010. The program is targeted to therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions; to reduce the long-term growth of health care costs in the United States; or to significantly advance the goal of curing cancer within 30 years. Allocation of the credit or grant also takes into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences. The credit or grant is only available to taxpayers with no more than 250 employees.
About Pharmalead Therapeutics / Invivis Inc.:
